Fig. 2
From: Cancer network activity associated with therapeutic response and synergism
CNA-IC50 correlation discriminates drugs and therapies. a Global distribution of PCCs between CNA values and IC50 profiles for all cancer cell lines and drugs, respectively. b Top panel, distribution of PCCs for drugs that target a single network node (i.e. targeted therapies) versus drugs that target multiple nodes and/or broad processes. The Wilcoxon test p values for the comparison of distributions are shown; gray distributions correspond to random permutations of CNA and cancer cell line correspondences. Bottom panel, distribution of PCCs for drugs that target CTKs or STKs. c Significant differences (PCCs, empirical p < 0.05) between drugs originally assigned to a different Class, Targeted Family, or Effector Pathway [8]